ArticleArquivos de neuro-psiquiatria2026
Cognitive impairment on the Alzheimer's Disease Centers' Uniform Data Set Version 3 Neuropsychological Test Battery in a Peruvian population with progressive supranuclear palsy.
Article in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Research on the cognitive profile in progressive supranuclear palsy (PSP) has been scarce in Latin America. Objective: To outline the demographic, clinical, and cognitive profile of Peruvian PSP patients living in Lima, Peru. We sought to determine the relationship between first clinical symptoms and specific cognitive abilities. Methods: A cross-sectional study of 34 PSP subjects. We used the Uniform Data Set Version 3 Neuropsychological Battery (UDS3-NB), which possesses normative data for the Peruvian population, to assess global and specific cognitive functions. We also performed correlation analyses to determine the relationship between presenting clinical symptoms (parkinsonism, postural instability, and cognitive impairment) and cognitive functioning. Results: The mean age was 68 years, and mean schooling was 12.1 years in this cohort. The most common initial clinical symptom was parkinsonism (55.9%), followed by postural instability (23.5%) and dementia (20.6%). Our cohort showed poor performance on global cognition, with selective impairment of processing speed, executive function, and episodic memory. Attentional and visuospatial skills were mildly affected, with partial preservation of naming. There was no significant relationship between the initial clinical symptoms and global cognition, except for a slight correlation between parkinsonism and visuospatial function (r = 0.18; Conclusion: We found that PSP patients in Peru had extensive impairment in executive function, processing speed, and episodic memory, with relatively preserved naming, consistent with other international cohorts. We did not find a correlation between initial clinical signs and cognitive profile, suggesting that an interdisciplinary approach is needed to evaluate patients with suspicion for PSP. Longitudinal studies are needed to more clearly define the progression of neuropsychiatric symptoms in PSP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.